Cefepime

• UNSPSC Description:

  Cefepime (BMY-28142) is a broad-spectrum and cross the blood-brain barrier cephalosporin. Cefepime shows antibacterial effects against both Gram-positive and Gram-negative aerobic bacteria. Cefepime induces neurotoxicity[1][2][3][4].

• Target Antigen:

  Antibiotic; Bacterial; Penicillin-binding protein (PBP)

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cefepime.html

• Purity:

  99.78

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)|H2O : 100 mg/mL (ultrasonic)

• Smiles:

  C[N+]1(CC(CS[C@]2([H])[C@@H]3NC(/C(C4=CSC(N)=N4)=N\OC)=O)=C(C([O-])=O)N2C3=O)CCCC1

• Molecular Weight:

  480.56

• References & Citations:

  [1]Yahav D, et al. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis. 2007 May;7(5):338-48. |[2]Barradell LB, Bryson HM. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1994;47(3):471-505.|[3]Payne LE, et al. Cefepime-induced neurotoxicity: a systematic review. Crit Care. 2017 Nov 14;21(1):276. doi: 10.1186/s13054-017-1856-1. |[4]Máthé A, et al. The effect of different doses of cisplatin on the pharmacokinetic parameters of cefepime in mice. Lab Anim. 2006 Jul;40(3):296-300.bioRxiv. 2024 May 10.|Emerg Microbes Infect. 2024 Dec;13(1):2321981.|J Antibiot (Tokyo). 2023 Feb 1.|Patent. US20240209004A1.|Pharmaceutics. 2023 Nov 30, 15(12), 2705.|Vet Microbiol. 2024 May, 292, 110046.|Animal Diseases. 02 November 2021.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  88040-23-7